-->

Tag: Immune Checkpoint Inhibitors

Home / Immune Checkpoint Inhibitors

Categories

Durvalumab is approved by the USFDA for limited-stage small cell lung cancer

 On December 4, 2024, the Food and Drug Administration sanctioned durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose condition remains stable after...
immune-checkpoint-inhibitors

Neoadjuvant/adjuvant nivolumab is approved by the USFDA for resectable non-small cell lung cancer

 On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded b...
immune-checkpoint-inhibitors

Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

 CAR immune Cell therapyChimeric Antigen Receptor (CAR) immune cell therapy has transformed the treatment of cancer, especially for hematological cancers. Its effectiveness notwithstanding, it still ...
immune-checkpoint-inhibitors

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

CancerFax is the most trusted online platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies.

Send your medical reports and get a free analysis.

🌟 Join us in the fight against cancer! 🌟

Привет,

CancerFax — это самая надежная онлайн-платформа, призванная предоставить людям, столкнувшимся с раком на поздних стадиях, доступ к революционным клеточным методам лечения.

Отправьте свои медицинские заключения и получите бесплатный анализ.

🌟 Присоединяйтесь к нам в борьбе с раком! 🌟